 | Up a level |
McClung, Michael R; O'Donoghue, Michelle L; Papapoulos, Socrates E; Bone, Henry; Langdahl, Bente; Saag, Kenneth G; Reid, Ian R; Kiel, Douglas P; Cavallari, Ilaria; Bonaca, Marc P; Wiviott, Stephen D; de Villiers, Tobias; Ling, Xu; Lippuner, Kurt; Nakamura, Toshitaka; Reginster, Jean-Yves; Rodriguez-Portales, Jose Adolfo; Roux, Christian; Zanchetta, José; Zerbini, Cristiano A F; ... (2019). Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. The lancet. Diabetes & endocrinology, 7(12), pp. 899-911. Elsevier 10.1016/S2213-8587(19)30346-8
Black, Dennis M; Reid, Ian R; Boonen, Steven; Bucci-Rechtweg, Christina; Cauley, Jane A; Cosman, Felicia; Cummings, Steven R; Hue, Trisha F; Lippuner, Kurt; Lakatos, Peter; Leung, Ping Chung; Man, Zulema; Martinez, Ruvie Lou Maria; Tan, Monique; Ruzycky, Mary Ellen; Su, Guoqin; Eastell, Richard (2012). The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of bone and mineral research, 27(2), pp. 243-54. Hoboken, N.J.: Wiley-Blackwell 10.1002/jbmr.1494
